Who Generates More Revenue? Vertex Pharmaceuticals Incorporated or BioMarin Pharmaceutical Inc.

Vertex's Revenue Soars: Outpacing BioMarin by 4x in 2023

__timestampBioMarin Pharmaceutical Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014751040000580415000
Thursday, January 1, 20158898950001032336000
Friday, January 1, 201611168540001702177000
Sunday, January 1, 201713136460002488652000
Monday, January 1, 201814912120003047597000
Tuesday, January 1, 201917040480004162821000
Wednesday, January 1, 202018604550006205683000
Friday, January 1, 202118462750007574400000
Saturday, January 1, 202220960390008930700000
Sunday, January 1, 202324192260009869200000
Monday, January 1, 2024285391500011020100000
Loading chart...

Unleashing insights

Vertex vs. BioMarin: A Revenue Showdown

In the competitive world of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outpaced BioMarin Pharmaceutical Inc. in revenue generation. Starting in 2014, Vertex's revenue was slightly behind BioMarin's, but by 2023, Vertex's revenue surged to nearly four times that of BioMarin. This remarkable growth trajectory highlights Vertex's strategic advancements and market positioning.

A Decade of Growth

From 2014 to 2023, Vertex's revenue increased by an impressive 1,600%, while BioMarin's revenue grew by approximately 220%. This stark contrast underscores Vertex's ability to capitalize on market opportunities and innovate within the pharmaceutical industry. As we look to the future, the question remains: Can BioMarin close the gap, or will Vertex continue to dominate the revenue race?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025